Cost-effectiveness analysis of anlotinib plus chemotherapy with or without benmelstobart versus chemotherapy alone for extensive-stage small-cell lung cancer in China

Cost-effectiveness analysis of anlotinib plus chemotherapy with or without benmelstobart versus chemotherapy alone for extensive-stage small-cell lung cancer in China

ObjectivesThe ETER701 trial demonstrated that benmelstobart combined with anlotinib and etoposide-carboplatin (EC) significantly extends survival in patients with extensive-stage small cell lung cancer (ES-SCLC), setting a new record for median overall survival. In contrast, anlotinib plus EC only s...

Full description

Saved in:

Bibliographic Details
Main Authors:	Caicong You, Jiahao Zhang, Jianying Lei, Wu Fu, Bin Zheng, Maobai Liu, Na Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Oncology
Subjects:	cost-effectiveness benmelstobart anlotinib extensive-stage small-cell lung scenario analysis R software
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1484650/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness analysis of benmelstobart, anlotinib, and chemotherapy in extensive-stage small-cell lung cancer
by: Maojin You, et al.
Published: (2024-11-01)

Cost-effectiveness analysis of durvalumab with chemotherapy and maintenance durvalumab with or without olaparib for advanced endometrial cancer
by: Jiahao Zhang, et al.
Published: (2025-01-01)

First-line treatment with zolbetuximab plus CAPOX for ClDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis
by: Jianying Lei, et al.
Published: (2024-11-01)

Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study
by: Jiaxuan Liu, et al.
Published: (2025-01-01)

Cost-effectiveness of nivolumab combined with chemotherapy as a first-line therapy for patients with unresectable or metastatic urothelial carcinoma
by: Jingwen Lin, et al.
Published: (2024-12-01)

Efficacy and safety of anlotinib as maintenance treatment in extensive-stage small cell lung cancer: a single-armed single center retrospective study
by: Jin Xiong, et al.
Published: (2025-01-01)

Octreotide plus IBI-318 plus anlotinib in the treatment of multiple neuroendocrine metastases of unknown primary lesions: a case report
by: Haoyue Qin, et al.
Published: (2024-12-01)

Rapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4‐UT Without PD‐L1 Expression: A Case Report and Review of Literature
by: Yuanhang Wang, et al.
Published: (2024-12-01)

First-line benmelstobart plus anlotinib and chemotherapy in advanced or metastatic/recurrent esophageal squamous cell carcinoma: a multi-center phase 2 study
by: Ning Li, et al.
Published: (2024-11-01)

Dramatic response of advanced pulmonary sarcomatoid carcinoma to tislelizumab combined with anlotinib: a case report
by: Ranran Li, et al.
Published: (2025-02-01)

The efficacy and safety of anlotinib plus PD-1 inhibitor in locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) patients who progressed on prior immune checkpoint inhibitors (ICIs): a retrospective real-world study (NCT 04984096)
by: Xueru Zhu, et al.
Published: (2025-12-01)

Efficacy and safety of anlotinib combined with immune checkpoint inhibitors and platinum-containing chemotherapy for later-line advanced non-small cell lung cancer: a retrospective three-arm real-world study using propensity-score matching
by: Zeyang Wang, et al.
Published: (2024-11-01)

Rapid health technology assessment of anlotinib in treatment of advanced non-small cell lung cancer
by: Shan SHEN, et al.
Published: (2021-10-01)

A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)
by: Hua-Jun Chen, et al.
Published: (2025-01-01)

The Efficacy and Safety of Albumin‐Bound Paclitaxel Combined With Anlotinib and PD‐1/L1 Inhibitors For Treating Patients With Extensive‐Stage Small Cell Lung Cancer and Brain Metastasis: A Retrospective Cohort Study
by: Xiaobing Li, et al.
Published: (2024-12-01)

Anlotinib combined with tislelizumab in the treatment of primary small cell neuroendocrine carcinoma of the prostate: a case report and literature review
by: Xin Fei, et al.
Published: (2024-12-01)

Penpulimab and Anlotinib in PDL1 high-expression pulmonary giant cell carcinoma with cerebral metastases: case report and review
by: Minghong Xie, et al.
Published: (2024-12-01)

Case Report: Efficacy of anlotinib and sintilimab in treating lung adenocarcinoma with RET fusion and PD-L1 expression
by: Hejing Bao, et al.
Published: (2024-11-01)

Case report: Favorable efficacy of combined afatinib and anlotinib treatment in a lung adenocarcinoma patient harboring uncommon EGFR L858M/L861R mutations
by: Yueming He, et al.
Published: (2024-11-01)

Efficacy and safety of PD‐1 monoclonal antibody combined with interferon‐alpha 1b and anlotinib hydrochloride as the second‐line therapy in patients with unresectable advanced melanoma: A retrospective study
by: Bolun Zhao, et al.
Published: (2024-08-01)

Anlotinib plus chemotherapy as a first-line treatment for gastrointestinal cancer patients with unresectable liver metastases: a multicohort, multicenter, exploratory trial
by: Jun-Wei Wu, et al.
Published: (2024-12-01)

Efficacy and safety of immunotherapy combined with chemotherapy in patients with ES‐SCLC: A systematic review and network meta‐analysis of RCTs and RWSs
by: Runting Kang, et al.
Published: (2024-11-01)

Trastuzumab plus chemotherapy versus chemotherapy alone in HER2-positive gastric cancer treatment in Iran: a cost-effectiveness analysis
by: Sara Kaveh, et al.
Published: (2024-11-01)

Adenoid cystic carcinoma of the external auditory canal with pulmonary metastasis: A case report and literature review
by: Xi Yang, et al.
Published: (2024-12-01)

Anti-inflammatory coupled anti-angiogenic airway stent effectively suppresses tracheal in-stents restenosis
by: Yanan Zhao, et al.
Published: (2025-01-01)

Combination therapy using low‐dose anlotinib and immune checkpoint inhibitors for extensive‐stage small cell lung cancer
by: Han Li, et al.
Published: (2024-12-01)

Case report: Personalized management of treatment resistance in advanced NSCLC patients with mutated epidermal growth factor receptor: special examples and literature review
by: Jun Wang, et al.
Published: (2025-02-01)

Case report: A golden tail of immunotherapy: significant tail effect in a chemotherapy-resistant advanced pulmonary sarcomatoid carcinoma patient treated by Sintilimab combined with Anlotinib
by: Chenghao Fu, et al.
Published: (2024-11-01)

Corrigendum: Case report: A golden tail of immunotherapy: significant tail effect in a chemotherapy-resistant advanced pulmonary sarcomatoid carcinoma patient treated by Sintilimab combined with Anlotinib
by: Chenghao Fu, et al.
Published: (2024-11-01)

An Unexpected Response of Orbital Retinoblastoma to Inconsistent Systemic Chemotherapy Alone
by: Khitam F. Alhasseny, et al.
Published: (2024-10-01)

Safety and efficacy of Immune checkpoint Inhibitors (ICIs) plus chemotherapy versus chemotherapy alone for small cell lung cancer (SCLC): A systematic review and meta-analysis of randomized controlled trials
by: Xiaohong Mu, et al.
Published: (2025-01-01)

Comparative efficacy and safety of anti-HGF/MET pathway agents plus chemotherapy versus chemotherapy alone as first-line treatment in advanced gastric cancer: a protocol for a systematic review and meta-analysis
by: Chunyu Liu, et al.
Published: (2021-12-01)

Anlotinib as Maintenance Therapy After First-Line Chemotherapy Combined with Consolidation Radiation for Extensive-Stage Small Cell Lung Cancer
by: Jinbo Ma MD, et al.
Published: (2025-01-01)

Results from the IMpower132 China cohort: Atezolizumab plus platinum‐based chemotherapy in advanced non‐small cell lung cancer
by: Shun Lu, et al.
Published: (2023-02-01)

Analysis of ICIs alone or in combination rechallenged outcomes after progression from first-line ICIs plus chemotherapy in patients with advanced non-small cell lung cancer
by: Guisen Yin, et al.
Published: (2025-01-01)

Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review
by: Yu Liu, et al.
Published: (2020-11-01)

Determining optimal clinical target volume margins based on microscopic extracapsular extension of metastatic nodes in patients with non-small-cell lung cancer after chemotherapy or chemotherapy combined with immunotherapy
by: Yujiao Zhang, et al.
Published: (2024-11-01)

Effect of trilaciclib administered before chemotherapy in patients with extensive-stage small-cell lung cancer: A pooled analysis of four randomized studies
by: Ying Liu, et al.
Published: (2024-01-01)

Neoadjuvant programmed death ligand-1 with chemotherapy versus chemotherapy alone for limited-stage small-cell lung cancer: a retrospective study
by: Zhi Yang, et al.
Published: (2025-01-01)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in the Chinese healthcare system
by: Wenwang Lang, et al.
Published: (2025-01-01)